Loading
A phase 1/2 trial of TQB6411 in oesophageal cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer is a phase 1/2 interventional study registered as NCT07367516 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 105 participants planned, started 2026-02-12 and due to reach its primary completion in 2027-02. Interventions recorded: TQB6411 Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TQB6411, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/